Vamikibart Shows Early Safety in Uveitic Macular Edema - Takeaways - MDSpire
Commentary & Perspectives

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

  • By

  • Kerri Miller

  • May 7, 2026

  • 3 min

Share

  • 1

    DOVETAIL trial assessed vamikibart for noninfectious uveitic macular edema.

  • 2

    39% of patients with dexamethasone faced intraocular pressure increases.

  • 3

    No significant cataract formation or sustained pressure rises with vamikibart.

  • 4

    Promising visual outcomes observed, but caution due to trial limitations.

  • 5

    No competing interests declared by authors.

  • 6

    Two phase 3 trials (MEERKAT, SANDCAT) continue evaluation.

Original Source(s)

Vamikibart Shows Early Safety in Uveitic Macular Edema

  • by Kerri Miller

  • May 7, 2026

Related Content

Phase 3 Win for TED Therapy

Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease

  • May 8, 2026

  • 3 min
Retinal Ischemia as Stroke Warning

Retrospective study investigates links between acute ischemic ocular events and increased stroke risk

  • May 8, 2026

  • 3 min
Chatbots Enter Retinal Care

New research shows how conversational AI might improve patient understanding and engagement in retinal detachment pathways

  • May 7, 2026

  • 3 min